Immutep (IMMP) announces that patient enrolment has been completed in the investigator-initiated EFTISARC-NEO trial. EFTISARC-NEO is evaluating eftilagimod alpha in combination with radiotherapy plus KEYTRUDA in the neoadjuvant setting for patients with resectable soft tissue sarcoma, STS. The Phase II trial conducted by the Maria Skodowska-Curie National Research Institute of Oncology in Warsaw, the national reference centre for STS in Poland, has reached its enrolment target of 40 patients.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP: